geboren 1965 in Karlsruhe

Ausbildung und Qualifikation

Beruflicher Werdegang

Forschungsschwerpunkt

Evidenzbasierte Medizin, Entwicklung und Durchführung von systematischen Reviews und Meta-Analysen.

Maligne Lymphome, insbesondere die Planung und Durchführung von klinische Studien in den Phasen I-III zur Primär- und Rezidivtherapie bei Patienten mit Non-Hodgkin-Lymphomen, Hodgkin-Lymphomen und CLL.

Mitgliedschaften

• Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO)
• Deutsche Krebsgesellschaft, Arbeitsgemeinschaft Internistischer Onkologen
• European Society of Medical Oncology (ESMO)
• Berufsverband der Niedergelassenen Hämatologen und Onkologen Deutschland (BNHO)
• Berufsverband der niedergelassenen Hämatologen und Onkologen Nordrhein (NIONo)

Verzeichnis der wissenschaftlichen Veröffentlichungen

1. In referierten Journalen publizierte Originalarbeiten

• Gaiser MR, Lorenzen S, Merx K, Trojan J, Ocvirk J, Ettrich TJ, Al-Batran SE, Schulz H, Homann N, Feustel HP, Schatz M, Kripp M, Schulte N, Heeger S, Vlassak S, Koch W, Hofheinz RD. Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: a thorough gender-specific analysis using the WoMo score. Cancer Med 2019 Aug;8(9):4169-4175

• Schildhaus HU, Schultheis AM, Rüschoff J, Binot E, Merkelbach-Bruse S, Fassunke J, Schulte W, Ko YD, Schlesinger A, Bos M, Gardizi M, Engel-Riedel W, Brockmann M, Serke M, Gerigk U, Hekmat K, Frank KF, Reiser M, Schulz H, Krüger S, Stoelben E, Zander T, Wolf J, Buettner R:  MET amplification status in therapy-naive adeno- and sqamous cell carcinoma oft he lung. Clin Cancer Res 2015; 21(4): 907-15

• Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen Ch., Rüdiger T, Borchmann P, Schnell R, Diehl V, Engert A and Reiser M. Rituximab in relapsed lymphocyte-predominant Hodgkin´s lymphoma: Long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG) . Blood. 2008;111:109-11.
• Schulz H, Bohlius JF, Reiser M, Skoetz N, Trelle S, Kober Th, Schwarzer G, Herold M, Dreyling M, Hallek M, Engert A. Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis. J Natl Cancer Inst 2007;99: 706 – 14
• Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Jensen M, Staib P, Schinköthe T, Hübel K, Schnell R, Josting A, Engert A. A new combination of alemtuzumab and fludarabine (FluCam) in patients with relapsed or refractory chronic lymphocytic leukemia is safe and effective: results of a phase-II pilot-study. J Clin Oncol 2005 Oct, 23 (28): 7024-7031
• Dietlein M, Pels H, Schulz H, Staak O, Borchmann P, Schomacker K, Fischer T, Eschner W, von Strandmann EP, Schicha H, Engert A, Schnell R. Imaging of central nervous system lymphomas with iodine-123 labeled rituximab. Eur J Haematol 2005: 74: 1–5.
• Rothe A, Schulz H, Elter T, Engert A. Rituximab monotherapy is effective in patients with poor risk refractory aggressive non Hodgkin’s lymphoma. Haematologica 2004; 89: 857-876
• Schulz H, Pels H, Schmidt-Wolf I, Zeelen U, Germing U, Engert A. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 2004 Jun;89 (6):753-4.
• Rehwald U1 , Schulz H1 , , Reiser M, Sieber M, Rüdiger T, Müller-Hermelink K, Diehl V, Engert A. Treatment of relapsed CD20-positive Hodgkin’s lymphoma with the monoclonal antibody rituximab is effective and well tolerated. Results of a phase-II trial of the GHSG. Blood Jan 15;101(2):420-4 (2003) 1both authors contributed equally
• Pels H, Schmidt-Wolf IGH, Glasmacher A, Schulz H, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Deckert M, Fimmers R, Helmstaedter C, Atasoy A, Klockgether T, Schlegel U. Primary CNS lymphoma: Results of a pilot/phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. JCO 21 (24): 4489-4495, 2003.
• Pels H, Schulz H, Manzke O, Hom E, Thall A, Engert A. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J Neuro-Oncol 59: 213-216 (2002)
• Pfitzner T, Reiser M, Barth S, Borchmann P, Schulz H, Schinköthe T, Oberhäuser F, Wessels J, Tur M, Diehl V, Engert A. Quantitative molecular monitoring of residual tumor cells in chronic lymphatic leukaemia. Ann Hematol 81 (5): 258-266 (2002)
• Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Hallek M, Aulitzky WE, Hensel M, Herold M, Huhn D, Knauf W, Diehl V, Engert A. Phase-II study of a combined immuno-chemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 100 (9): 3115-20 (2002)
• Pfitzner T, Engert A, Wittor H., Schinköthe T, Winkler U, Schulz H, Diehl V, Barth S. A real-time PCR assay for the quantification of residual malignant cells in monoclonal B-cell lymphomas. Leukemia 14: 754-766 (2000).
• Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 94: 2217-2224 (1999).
• Schulz H, Karau A, Filsinger S, Schoels M, Kabelitz D, Richter R, Hansch GM. Tubular epithelial cells as accessory cells for superantigen-induced T cell activation. Exp Nephrol. 1998 Jan-Feb;6(1):67-73.

2. Buchbeiträge

• Schulz H, Rehwald U, Staak JO, Engert A. Immuntherapeutische Konzepte. In: Hallek M, Emmerich B: Chronische lymphatische Leukämie, Uni-Med Verlag AG, Bremen: 106-112 (2001).

3. Übersichtsartikel

• Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, Dreyling M, Herold M, Schwarzer G, Hallek M, Engert A Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003805
• Naumann,F.; Weingart,O.; Kruse,E.; Schulz H.; Bohlius,J.; Hulsewede,H.; Engert,A. Fifth biannual report of the Cochrane Haematologic Malignancies Group-Focus on multiple myeloma. JNatl. Cancer Inst 2006 98 (16) E2
• Borchmann P, Schnell R, Schulz H, Engert A. Antibody-based immunotherapy of Hodgkin’s lymphoma. Current opinion in investigational drugs 2005: 5 (12)
• Rehwald U, Schulz H, Engert A. Monoclonal antibody rituximab for treatment of CD20-positive Hodgkin’s lymphoma: The German experience. Submitted
• Pels H, Schulz H, Schlegel U, Engert A. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature. Onkologie 26: 351-354, 2003
• Borchmann P, Engert A, Schulz H. Treatment of relapsed CD20-positive Hodgkin’s lymphoma with rituximab is effective and well tolerated: An update of a phase II trials of the German Hodgkin’s Lymphoma Study Group. Cancer Conference Highlights 7 (1), 2003.
• Schulz H, Rehwald U, Schnell R, Josting A, Borchmann P, Engert A. Treatment of relapsed CD20-positive Hodgkin’s lymphoma with the monoclonal antibody rituximab. Am J Onc Rev 2 (3): 129-137 (2003)
• Schulz H, Engert A. A patient with chronic lymphocytic leukemia treated with rituximab and fludarabine. Case Studies in Lymphoma 1 (2): 1-8 (2002)
• Schnell R, Borchmann P, Schulz H, Engert A. Current strategies of antibody-based treatment in Hodgkin’s disease. Ann Oncol 13. Suppl 1: 57-66 (2002)
• Engert A, Schulz H. Rituximab in combination with fludarabine for the treatment of patients with chronic lymphocytic leukemia. Biological Therapy of Lymphoma: Vol 5 (1): 6-8 (2002)
• Staak O, Schnell R, Schulz H, Diehl V, Engert A. Antikörper-vermittelte Immuntherapie bei malignen Erkrankungen. Arzneimitteltherapie 12: 378-386 (2000).
• Schulz H, Winkler U, Staak JO, Engert A. The monoclonal antibodies Campath-1H and Rituximab in the therapy of chronic lymphocytic leukemia. Onkologie 23: 526-532 (2000).
• Schulz H, Winkler U, Engert A, Diehl V. Lymphknotenvergrößerung – was steckt dahinter? Der Hausarzt: 23-27 (1999)